BMO Capital analyst Evan David Seigerman lowered the price target on Abbvie (NYSE: ABBV) to $180.00 (from $195.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE